Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while rat models treated with letrozole and dihydrotestosterone exhibit altered sterol, leukotriene, and steroid hormone profiles similar to human PCOS, significant differences remain.

This study found that dihydrotestosterone treatment may be more beneficial for height in children with 5-α-reductase type 2 deficiency compared to testosterone enanthate, especially in the prepubertal period.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This review discusses the role of genetic mutations and environmental endocrine disruptors in insufficient androgen action, which can result in conditions like hypospadias, cryptorchidism, and micropenis, during male fetal development.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This study engineered a bioluminescent yeast strain responsive to androgenic chemicals, demonstrating rapid and sensitive detection suitable for high-throughput screening and environmental monitoring.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

This review discusses 46,XY disorders of sex development caused by defects in androgen production and highlights the need for long-term care from experienced multidisciplinary teams, but it reports no new clinical findings.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This review discusses the production, role, and measurement of dihydrotestosterone (DHT) in various disorders of sexual development but does not report new clinical results.

In a testosterone-induced BPH rat model, this study found that ursolic acid treatment significantly reduced prostate weight and hormone levels, suggesting it may inhibit BPH development.

This study found that testosterone and 5α-dihydrotestosterone affect human sebocytes differently depending on the skin region, with spironolactone inhibiting their proliferation and counteracting androgen effects in facial sebocytes.

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This study found that metformin treatment during pregnancy in women with PCOS was associated with higher SHBG levels in newborns, but did not affect androgen or estrogen levels at birth.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This article discusses the functions of the enzyme 17beta-HSD10, including its role in steroid metabolism and potential links to Alzheimer's disease, but reports no new experimental findings.

This study found that finasteride decreases DHT/T levels more significantly in the vertex scalp hair than in the occipital hair of patients with male pattern baldness.

This study found that androgen binding in male rat livers involves specific androgen receptors, which decrease with castration and are inducible in female livers with testosterone.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study suggests that DHT may have a less potent effect on the prostate compared to testosterone while maintaining safety and similar effects on erythropoiesis and lipids.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.

This study found that testosterone may promote glioblastoma progression by being converted into dihydrotestosterone, which enhances cell proliferation, migration, and invasion in GBM cell lines.

This study reported higher dihydrotestosterone and testosterone levels in balding Korean and Caucasian subjects compared to non-balding controls, with variations suggesting racial differences in androgen metabolism.

Minocycline may cause hair loss by increasing DHT levels, but finasteride can help counteract this effect.

Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.